吉西他滨联合奥沙利铂治疗复发或难治性NHL的临床疗效

doi:10.3969/j.issn.1671-7171.2021.12.019

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1118 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of gemcitabine combined with oxaliplatin in the treatment of recurrent refractory non-hodgkin's lymphoma (NHL). 【Methods】The clinical data of 86 patients with relapsed refractory NHL in our hospital from July 2015 to July 2018 were retrospectively analyzed. According to the treatment methods, the control group (43 cases) was treated with vinorelbine combined with oxaliplatin, while the observation group (43 cases) was treated with gemcitabine combined with oxaliplatin. The therapeutic effects of the two groups were compared. 【Results】The clinical effective rate of the observation group was 72.09% (31/43), which was higher than that of the control group (62.79%, 27/43). However, the difference was not statistically significant (χ²= 0.847, P=0.357).After treatment, the KPS scores of the two groups were both higher than corresponding KPS scores before treatment (P<0.05), while the difference of post-treatment between the control group and the observation group was not statistically significant (P>0.05).The incidence of thrombocytopenia, gastrointestinal reactions and peripheral nerve symptoms in the observation group was lower than that in the control group (P<0.05).After 12 months of follow-up, the progression-free survival rate and overall survival rate were 58.14% and 81.40% in the study group,respectively. If they were compared to the progression-free survival rate (55.81%) and overall survival rate (76.74%) in the control group, the difference was not statistically significant (χ²=0.047, P=0.827; χ²=0.281, P=0.596). 【Conclusion】Combined use of gemcitabine and oxaliplatin in the treatment of relapsed and refractory NHL has the same effect as vinorelbine combined with oxaliplatin.

Key words： Lymphoma, Non-Hodgkin/DT Deoxycytidine/AA Organoplatinum Compounds/PD Treatment Outcome

Received: 18 January 2021

PACS:

R733.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Aziguli
	MAO Min
	Muhebaier·Abuduer
	et al

Cite this article:

Aziguli,MAO Min,Muhebaier·Abuduer, et al. Effect Analysis of Gemcitabine Combined with Oxaliplatin in the Treatment of Relapsed or Refractory NHL[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(12): 1826-1828.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.12.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I12/1826

[1] 杨帆,孙鹏飞,那曼丽,等.脊柱原发非霍奇金淋巴瘤的影像和病理表现特征[J].放射学实践,2018,33(1):68-73.
[2] 王天怡, 汤静燕, 李本尚. 嵌合抗原受体T细胞治疗非霍奇金淋巴瘤的最新研究进展[J].国际输血及血液学杂志, 2017, 40(1):56-61.
[3] 李春艳, 薛恺, 张群岭. 聚乙二醇化重组人G-CSF在以CHOP为基础方案的非霍奇金淋巴瘤中的应用[J].中国癌症杂志, 2017, 27(12):970-975.
[4] 孟红艳,王晶晶,高小虎.奥沙利铂联合改良吉西他滨治疗晚期胆系肿瘤临床疗效及安全性观察[J].实用癌症杂志,2019,34(3):466-468.
[5] 解国清, 邵艳, 李雷, 等. 替吉奥联合奥沙利铂以及吉西他滨联合顺铂治疗晚期三阴性乳腺癌的临床效果比较[J].中国综合临床, 2019, 35(3):259-262.
[6] 石远凯, 牛奕. 美国国家综合癌症网非霍奇金淋巴瘤治疗指南2007年第一版介绍[J].中华肿瘤杂志, 2007, 29(11):879-880.
[7] THERASSE P, ARBUCK S G, EISENHAUER E A,et al.New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst,2000, 92(3):205-216.
[8] 吴萍,敬小梅,余思思.GEMOX与GDP方案治疗复发或难治性非霍奇金淋巴瘤的疗效比较[J].医学临床研究,2018,35(6):1053-1055.
[9] 黄斯勇, 刘利, 梁英民,等. 双次自体造血干细胞移植治疗侵袭性非霍奇金淋巴瘤的疗效和预后分析[J].国际输血及血液学杂志, 2017, 40(6):461-467.
[10] 朱娴雅,杨顺娥,李国辉, 等.GEMOX方案和NO方案治疗复发或难治性非霍奇金淋巴瘤的疗效比较[J].国际肿瘤学杂志,2018,45(9):574-576.
[11] 张呈,苏铭俊,容庭杰, 等.R-GEMOX方案治疗复发难治B细胞性非霍奇金淋巴瘤的疗效[J].现代肿瘤医学,2018,26(24):4008-4010.
[12] 付茂琦,余祥彬.长春瑞滨纳米乳剂的制备及稳定性影响因素考察[J].国际药学研究杂志,2018,45(9):709-713.
[13] 朱兆承, 王生, 胡彦辉,等. 中药内服联合外浴治疗42例奥沙利铂致蓄积性周围神经毒性的临床分析[J].安徽医药, 2017, 21(9):1696-1698.
[14] 闫世彬,陈忠光,马德亮, 等.含吉西他滨的联合化疗方案治疗难治性非霍奇金淋巴瘤疗效[J].中国实验血液学杂志,2017,25(5):1415-1419.